2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-19937
    Saroglitazar 495399-09-2 99.10%
    Saroglitazar is a novel peroxisome proliferator-activated receptor (PPAR) agonist with predominant PPARα and moderate PPARγ activity with EC50 values of 0.65 pM and 3 nM in HepG2 cells, respectively.
    Saroglitazar
  • HY-105185
    Fidarestat 136087-85-9 99.63%
    Fidarestat (SNK 860) is an inhibitor of aldose reductase, with IC50s of 26 nM, 33 μM, and 1.8 μM for aldose reductase, AKR1B10 and V301L AKR1B10, respectively; Fidarestat (SNK 860) has the potential to treat diabetic disease.
    Fidarestat
  • HY-135954
    PDK4-IN-1 2310262-10-1 98.82%
    PDK4-IN-1 is an anthraquinone derivative and a potent and orally active pyruvate dehydrogenase kinase 4 (PDK4) inhibitor with an IC50 value of 84 nM. PDK4-IN-1 potently represses cellular transformation and cellular proliferation and induces apoptosis. PDK4-IN-1 has antidiabetic, anticancer and anti-allergic activity.
    PDK4-IN-1
  • HY-B0283
    Acipimox 51037-30-0 99.86%
    Acipimox (K-9321), a nicotinic acid analogue, is an antilipolytic compound. Acipimox stimulates leptin releas, inhibits lipolysis and suppresses systemic levels of free fatty acids (FFAs) and improves insulin sensitivity.
    Acipimox
  • HY-B0287
    Clofibrate 637-07-0 99.61%
    Clofibrate is an agonist of PPAR, with EC50s of 50 μM, ～500 μM for murine PPARα and PPARγ, and 55 μM, ～500 μM for human PPARα and PPARγ, respectively.
    Clofibrate
  • HY-B0422
    Nateglinide 105816-04-4 99.51%
    Nateglinide, a D-phenylalanine derivative, is an orally active and short-acting insulinotropic agent and a DPP IV inhibitor. Nateglinide inhibits ATP-sensitive K+ channels in pancreatic β-cells. Nateglinide is used for the treatment of type 2 (non-insulin-dependent) diabetes mellitus.
    Nateglinide
  • HY-17037
    Pirenzepine dihydrochloride 29868-97-1 99.84%
    Pirenzepine (LS 519) dihydrochloride is a selective M1 mAChR (muscarinic acetylcholine receptor) antagonist. Pirenzepine dihydrochloride reduces gastric acid secretion and reduces muscle spasm, can be used in peptic ulcers research. Pirenzepine dihydrochloride shows anti-proliferative activity to cancer cells.
    Pirenzepine dihydrochloride
  • HY-18522
    AA26-9 1312782-34-5 99.42%
    AA26-9 is a potent and broad spectrum serine hydrolase inhibitor. AA26-9 targets included serine peptidases, lipases, amidases, esterases, and thioesterases. AA26-9 shows inhibitory activity against approximately 1/3 of the 40+ serine hydrolases detected in immortalized T cell lines .
    AA26-9
  • HY-21065
    Tienilic acid 40180-04-9 99.69%
    Tienilic acid (Ticrynafen; ANP 3624) acts as a diuretic hypotensive agent. However, Tienilic acid induces hepatotoxicity. Tienilic acid is converted into electrophilic metabolites by cytochrome P450 (CYP) in vitro.
    Tienilic acid
  • HY-D0195
    Acesulfame potassium 55589-62-3 ≥98.0%
    Acesulfame potassium is a synthetic sweetener. Long-term use of Acesulfame potassium can affect cognitive function, possibly by altering the neurometabolic functions in mice. Acesulfame potassium can suppress autophagic degradation of PD-L1 in RIL-175 and SK-Hep1 cells through the ERK1/2-mTORC1-ULK1 pathway, which may be related to immune evasion in cancer cells. Acesulfame potassium can be used in research on neurological diseases, metabolic disorders, cancer, and immune evasion.
    Acesulfame potassium
  • HY-D0889
    Glycylglycine 556-50-3 ≥99.0%
    Glycylglycine is a non-selective glycylglycine dipeptidase substrate and iNOS inhibitor. Glycylglycine can cross the cell membrane by passive diffusion and is hydrolyzed to glycine in the cell, participating in energy metabolism and antioxidant processes. Glycylglycine promotes spermatogonial stem cells (SSCs) proliferation, inhibits astrocyte overactivation and reduces nitric oxide (NO) release, while upregulating the expression of neurotrophic factors (such as PDGFA, FGF2, CNTF) to support nerve myelin repair. Glycylglycine can be used to study male reproductive biology (such as SSCs proliferation regulation) and neurodegenerative diseases (such as neuroprotective mechanisms in multiple sclerosis).
    Glycylglycine
  • HY-N0404
    Sinigrin 3952-98-5 99.97%
    Sinigrin is a major glucosinolate present in plants of the Brassicaceae family. Sinigrin inhibits early-stage adipogenesis of 3T3-L1 adipocytes through the AMPK and MAPK signaling pathways. Sinigrin has potent anti-oxidant, anti-tumor and anti-inflammatory effects.
    Sinigrin
  • HY-N0532
    Morroniside 25406-64-8 ≥98.0%
    Morroniside has neuroprotective effect by inhibiting neuron apoptosis and MMP2/9 expression.
    Morroniside
  • HY-N1419
    Vaccarin 53452-16-7 98.47%
    Vaccarin is an active flavonoid glycoside associated with various biological functions. Vaccarin significantly promote wound healing and endothelial cells and fibroblasts proliferation in the wound site. Vaccarin ameliorates insulin resistance and steatosis by activating the AMPK signaling pathway.
    Vaccarin
  • HY-N1481
    Methyl linoleate 112-63-0 ≥98.0%
    Methyl linoleate, a major active constituent of Sageretia thea?fruit (HFSF), is a major anti-melanogenic compound. Methyl linoleate downregulates microphthalmia-associated transcription factor (MITF)?and tyrosinase-related proteins.
    Methyl linoleate
  • HY-N4187
    Licochalcone D 144506-15-0 ≥99.0%
    Licochalcone D, a flavonoid compound mainly existing in the root of Glycyrrhiza uralensis, is a potent and orally active inhibitor of NF-kappaB (NF-κB) p65. Licochalcone D possesses antioxidant, anti-inflammatory, anti-cancer properties.
    Licochalcone D
  • HY-N7135
    Tropolone 533-75-5 ≥98.0%
    Tropolone is a seven-membered non-benzenoid aromatic compound, which is the precursor of many Azulene derivatives. Tropolone is a potent mushroom tyrosinase inhibitor with an IC50 value of 0.4 μM. Its inhibitory effect can be achieved by dialysis or excess CU2+ Reversa. Tropolone exhibits broad anti-viral and anti-fungal activity and is synergistic upon co-treatment with nucleos(t)ide analog drugs. Tropolone is a promising candidate for research in osteosarcoma.
    Tropolone
  • HY-N9481
    Lipoteichoic acid 56411-57-5
    Lipoteichoic acid is an orally effect anti-inflammatory and antitumor agent. Lipoteichoic acid is a crucial immune molecule in Gram-positive bacteria that activates the complement system by inducing C3 and inhibiting CD55. Lipoteichoic acid regulates macrophage autophagy through the PI3K/Akt/mTOR pathway. Lipoteichoic acid induces lung damage in mice. Lipoteichoic acid inhibits the production of melanin.
    Lipoteichoic acid
  • HY-Y1667
    2,6-Dibromophenol 608-33-3 ≥98.0%
    2,6-Dibromophenol is an endogenous metabolite.
    2,6-Dibromophenol
  • HY-107321
    Azosemide 27589-33-9 99.48%
    Azosemide, a sulfonamide loop diuretic, is a potent NKCC1 inhibitor with IC50s of 0.246 μM and 0.197 μM for hNKCC1A and NKCC1B, respectively.
    Azosemide
Cat. No. Product Name / Synonyms Application Reactivity